CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, has successfully closed its $10.0 million public offering. The offering included 6,665,000 shares of common stock and Class A warrants to purchase up to 13,330,000 shares at a combined price of $1.50 per share and accompanying warrants.
The Class A warrants have an initial exercise price of $1.50 per share, are immediately exercisable, and will expire after five years. Maxim Group acted as the exclusive placement agent. Azitra plans to use the net proceeds for working capital and general corporate purposes. The offering was made pursuant to an effective SEC registration statement, with a final prospectus available on the SEC's website.
Azitra, Inc. (NYSE American: AZTR), una azienda biofarmaceutica in fase clinica specializzata in dermatologia di precisione, ha concluso con successo la sua offerta pubblica da 10,0 milioni di dollari. L'offerta ha incluso 6.665.000 azioni di comune e warrant di Classe A per l'acquisto di fino a 13.330.000 azioni a un prezzo complessivo di 1,50 dollari per azione e warrant ad essi associati.
I warrant di Classe A hanno un prezzo di esercizio iniziale di 1,50 dollari per azione, sono immediatamente esercitabili e scadranno dopo cinque anni. Maxim Group ha agito come agente esclusivo per il collocamento. Azitra prevede di utilizzare i proventi netti per il capitale di esercizio e scopi aziendali generali. L'offerta è stata effettuata in base a una dichiarazione di registrazione SEC efficace, con un prospetto finale disponibile sul sito web della SEC.
Azitra, Inc. (NYSE American: AZTR), una empresa biofarmacéutica en etapa clínica centrada en dermatología de precisión, ha cerrado con éxito su oferta pública de 10.0 millones de dólares. La oferta incluyó 6,665,000 acciones de acciones comunes y warrants de Clase A para comprar hasta 13,330,000 acciones a un precio combinado de 1.50 dólares por acción y sus warrants.
Los warrants de Clase A tienen un precio de ejercicio inicial de 1.50 dólares por acción, son ejercitables de inmediato y expirarán después de cinco años. Maxim Group actuó como agente exclusivo de colocación. Azitra planea utilizar los fondos netos para capital de trabajo y fines corporativos generales. La oferta se realizó de acuerdo con una declaración de registro de la SEC efectiva, con un prospecto final disponible en el sitio web de la SEC.
Azitra, Inc. (NYSE American: AZTR), 정밀 피부과에 중점을 둔 임상 단계의 생명공학 회사가 1천만 달러의 공모를 성공적으로 마감했습니다. 이번 공모에는 6,665,000주의 일반 주식과 A 클래스 전환사채가 포함되어 있으며, 13,330,000주를 주당 1.50 달러 및 관련 전환사채에 대한 가격으로 구입할 수 있습니다.
A 클래스 전환사채는 초기 행사 가격이 1.50 달러이며 즉시 행사 가능하고 5년 후 만료됩니다. Maxim Group이 독점 배치 대행사로 활동했습니다. Azitra는 순수익금을 운영 자본 및 일반 기업 목적에 사용할 계획입니다. 이번 공모는 유효한 SEC 등록 성명에 따라 진행되었으며, 최종 투자 설명서는 SEC 웹사이트에서 확인할 수 있습니다.
Azitra, Inc. (NYSE American: AZTR), une entreprise biopharmaceutique en phase clinique axée sur la dermatologie de précision, a réussi à clore son offre publique de 10,0 millions de dollars. L'offre comprenait 6 665 000 actions ordinaires et options de classe A pour acheter jusqu'à 13 330 000 actions à un prix combiné de 1,50 $ par action et les options associées.
Les options de classe A ont un prix d'exercice initial de 1,50 $ par action, sont immédiatement exerçables et expireront après cinq ans. Maxim Group a agi en tant qu'agent de placement exclusif. Azitra prévoit d'utiliser le produit net pour le fonds de roulement et les fins générales de l'entreprise. L'offre a été réalisée conformément à une déclaration d'enregistrement SEC efficace, avec un prospectus final disponible sur le site web de la SEC.
Azitra, Inc. (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzise Dermatologie spezialisiert hat, hat erfolgreich seine Öffentliche Platzierung von 10,0 Millionen US-Dollar abgeschlossen. Die Platzierung umfasste 6.665.000 Aktien von Stammaktien und Warrants der Klasse A zum Kauf von bis zu 13.330.000 Aktien zu einem kombinierten Preis von 1,50 US-Dollar pro Aktie und zugehörigen Warrants.
Die Warrants der Klasse A haben einen anfänglichen Ausübungspreis von 1,50 US-Dollar pro Aktie, sind unverzüglich ausübbar und verfallen nach fünf Jahren. Maxim Group fungierte als exklusiver Platzierungsagent. Azitra plant, die Nettomittel für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Die Platzierung wurde gemäß einer wirksamen SEC-Registrierungserklärung durchgeführt, das endgültige Prospekt ist auf der Website der SEC verfügbar.
- None.
- None.
The updated release reads:
AZITRA, INC. ANNOUNCES CLOSING OF
Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of an aggregate of 6,665,000 shares of its common stock, and Class A warrants to purchase up to 13,330,000 shares of common stock, at a combined public offering price of
Maxim Group LLC acted as the exclusive placement agent for the offering.
The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately
The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-280806), which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 23, 2024. The offering was made only by means of a prospectus which forms a part of the effective registration statement. A final prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained on the SEC’s website at www.sec.gov and may also be obtained by contacting Maxim Group LLC at 300 Park Avenue, 16th Floor,
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding Azitra’s anticipated use of proceeds therefrom.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties are described in our prospectus dated July 19, 2024 filed with the SEC on July 19, 2024. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725675771/en/
Norman Staskey
Chief Financial Officer
staskey@azitra.com
Source: Azitra, Inc.
FAQ
What was the total amount raised in Azitra's (AZTR) public offering?
How many shares and warrants were offered in Azitra's (AZTR) public offering?
What was the combined price per share and warrant in Azitra's (AZTR) offering?
What are the terms of the Class A warrants issued by Azitra (AZTR)?
Who acted as the placement agent for Azitra's (AZTR) public offering?
